Lipocine Gains Bullish New Coverage, With Stock (LPCN) Down 30% YTD

Clinical-stage biopharma Lipocine Inc. (NASDAQ: LPCN) receives a bullish Buy rating and $8 price target from H.C. Wainwright, as scientific recognition and pipeline progress fuel renewed investor interest.

A major catalyst for renewed optimism is the recent recognition of Lipocine’s LPCN 1148 candidate in the June 2025 edition of Hepatology, the leading journal of the American Association for the Study of Liver Diseases. The feature article, authored by Dr. Kevin Harris of the Mayo Clinic, spotlights LPCN 1148’s potential to address sarcopenia in men with cirrhosis, a market with few effective therapies beyond lifestyle modification. The publication of positive Phase 2 trial data, combined with the FDA’s fast track designation, underscores the growing credibility of Lipocine’s technology platform and its potential to address significant unmet medical needs.

The company is actively seeking partners to advance LPCN 1148, which could further accelerate development and commercialization if successful. Such recognition from the scientific community often precedes increased investor confidence, particularly in the biotech sector, where clinical milestones can rapidly shift sentiment.

H.C. Wainwright’s $8 price target implies more than 120% upside from current levels, reflecting confidence in Lipocine’s pipeline and technology. Despite this,

Lipocine’s pipeline extends beyond LPCN 1148. The company recently initiated a Phase 3 trial for LPCN 1154, a rapid-onset oral formulation of brexanolone for postpartum depression, with first patient dosing expected in Q2 2025. Analyst Yi Chen’s bullish outlook is largely anchored in the commercial prospects of LPCN 1154, which, if successful, could transform the company’s valuation profile.

Meanwhile, Lipocine is advancing LPCN 2401 for obesity management as an adjunct to GLP-1 therapies, and exploring partnership opportunities for LPCN 1107 (prevention of preterm birth) and the aforementioned LPCN 1154. The expansion of TLANDO partnerships, including a recent deal with Aché for Brazilian market rights and an exclusive agreement with Verity Pharma for North America, further diversifies the company’s revenue streams and global reach.

As always, careful monitoring of clinical milestones, partnership developments, and financial updates will be critical in assessing whether Lipocine can deliver on its promising potential and justify the bullish price targets now in play.